Forte Biosciences
FBRXForte Biosciences, Inc. (NASDAQ: FBRX) is a publicly traded, clinical-stage biopharmaceutical company based in the United States. The company's primary business focus is the research and development of live biotherapeutic products. These are defined as biological products that contain live organisms, such as bacteria, which are applied to treat or prevent disease. The company’s lead product candidate is FB-401, a topical live bacterial therapeutic. FB-401 is being investigated for the treatment of inflammatory skin diseases, with atopic dermatitis as its initial target indication. The therapeutic areas of focus for Forte Biosciences are inflammatory skin conditions and autoimmune disorders, placing its work within the dermatology and broader biotech sectors. Forte Biosciences has advanced FB-401 through clinical testing. The company has reported data from Phase 1/2 studies in patients with atopic dermatitis. Its development activities are centered on progressing this candidate through the clinical trial process to evaluate its safety and efficacy for potential regulatory approval.
FBRX · Stock Price
Historical price data
About
Forte Biosciences, Inc. (NASDAQ: FBRX) is a publicly traded, clinical-stage biopharmaceutical company based in the United States. The company's primary business focus is the research and development of live biotherapeutic products. These are defined as biological products that contain live organisms, such as bacteria, which are applied to treat or prevent disease. The company’s lead product candidate is FB-401, a topical live bacterial therapeutic. FB-401 is being investigated for the treatment of inflammatory skin diseases, with atopic dermatitis as its initial target indication. The therapeutic areas of focus for Forte Biosciences are inflammatory skin conditions and autoimmune disorders, placing its work within the dermatology and broader biotech sectors. Forte Biosciences has advanced FB-401 through clinical testing. The company has reported data from Phase 1/2 studies in patients with atopic dermatitis. Its development activities are centered on progressing this candidate through the clinical trial process to evaluate its safety and efficacy for potential regulatory approval.